Fentanyl transdermal - Hisamitsu

Drug Profile

Fentanyl transdermal - Hisamitsu

Alternative Names: Fentanyl citrate patch - Hisamitsu; Fentanyl citrate transdermal - Hisamitsu; FENTOS; FENTOS® TAPE; HFT-290

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hisamitsu Pharmaceutical
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Pain

Most Recent Events

  • 25 Sep 2017 Hisamitsu Pharmaceutical initiates a phase III trial for Cancer pain in Japan (Transdermal, Patch) (JapicCTI173717)
  • 13 Sep 2017 Hisamitsu Pharmaceutical completes a phase III trial for Cancer pain in Japan (Transdermal) (JapicCTI-163363) prior to September 2017
  • 31 Aug 2017 Hisamitsu Pharmaceutical files sNDA for 0.5mg dose of Fentanyl transdermal for Cancer pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top